Fascin Expression Predicts an Aggressive Clinical Course in Patients with Advanced Breast Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Jul 15

PMID 26170987

Citations 16

Authors

Kyueng-Whan Min

Seoung Wan Chae

Dong-Hoon Kim

Sung-Im DO

Kyungeun Kim

Hyun Joo Lee

Jin Hee Sohn

Jung-Soo Pyo

Dong Hyun Kim

Sukjoong Oh

Seon Hyeong Choi

Yong Lai Park

Chan Heun Park

Affiliations

Soon will be listed here.

Abstract

Fascin is an actin cross-linking protein, which regulates actin dynamics and filopodia or spike formation, as well as the epithelial-mesenchymal transition, and has been implicated in cell motility. Although, fascin is pivotal in mediating the aggressive behaviour of various types of cancer, its prognostic significance according to tumour stage has yet to be evaluated. Therefore, the present study investigated fascin expression in 194 patients diagnosed with invasive ductal carcinoma of the breast between 2000 and 2005. Fascin protein expression levels were evaluated by immunostaining on a tissue microarray, and the association between fascin expression and various clinicopathological parameters was analysed. Fascin expression was significantly correlated with various clinicopathological parameters, including high histological grade, tumour necrosis, resistance to adjuvant therapy, high expression of p53 and Ki-67 and specific therapeutic markers (oestrogen and progesterone receptor negativity; all P<0.05). Furthermore, univariate and multivariate analyses identified a significant association between fascin expression, and poor disease-free and overall survival, in late-stage breast cancer (all P<0.05). Therefore, fascin may be crucial in predicting aggressive tumour behaviour, particularly in patients with advanced-stage disease that has acquired the properties of migration and invasion.

Citing Articles

Comparative Analysis of Breast Cancer Metabolomes Highlights Fascin's Central Role in Regulating Key Pathways Related to Disease Progression.

AlMalki R, Al-Nasrallah H, Aldossry A, Barnawi R, Al-Khaldi S, Almozyan S Int J Mol Sci. 2024; 25(14).

PMID: 39063133 PMC: 11277536. DOI: 10.3390/ijms25147891.

The association of FSCN1 (rs852479, rs1640233) and HOTAIR (rs920778) polymorphisms with the risk of breast cancer in Egyptian women.

Galal E, Abdelhakam D, Ahmed L, Elhusseny Y, Sayed S, Eltaweel N Mol Biol Rep. 2024; 51(1):495.

PMID: 38587571 PMC: 11001669. DOI: 10.1007/s11033-024-09459-9.

AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling.

Ju G, Xing T, Xu M, Zhang X, Sun Y, Mu Z Neoplasia. 2024; 49:100972.

PMID: 38237535 PMC: 10828808. DOI: 10.1016/j.neo.2024.100972.

Fascin-1 in Cancer Cell Metastasis: Old Target-New Insights.

Sarantelli E, Mourkakis A, Zacharia L, Stylianou A, Gkretsi V Int J Mol Sci. 2023; 24(14).

PMID: 37511011 PMC: 10379093. DOI: 10.3390/ijms241411253.

Fascin-1: Updated biological functions and therapeutic implications in cancer biology.

Li C, Chan M, Liang S, Chang Y, Hsiao M BBA Adv. 2023; 2:100052.

PMID: 37082587 PMC: 10074911. DOI: 10.1016/j.bbadva.2022.100052.

References

Ogston K, Miller I, Payne S, Hutcheon A, Sarkar T, Smith I . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12(5):320-7. DOI: 10.1016/s0960-9776(03)00106-1. View

Feeley L, Mulligan A, Pinnaduwage D, Bull S, Andrulis I . Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 2013; 27(4):554-61. DOI: 10.1038/modpathol.2013.153. View

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

Jayo A, Parsons M . Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol. 2010; 42(10):1614-7. DOI: 10.1016/j.biocel.2010.06.019. View

Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M . Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer. 2007; 96(7):1118-26. PMC: 2360113. DOI: 10.1038/sj.bjc.6603690. View

Edwards R, Bryan J . Fascins, a family of actin bundling proteins. Cell Motil Cytoskeleton. 1995; 32(1):1-9. DOI: 10.1002/cm.970320102. View

Saaristo A, Karpanen T, Alitalo K . Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 2001; 19(53):6122-9. DOI: 10.1038/sj.onc.1203969. View

Xie J, Xu L, Wu J, Shen Z, Zhao Q, Du Z . Involvement of CYR61 and CTGF in the fascin-mediated proliferation and invasiveness of esophageal squamous cell carcinomas cells. Am J Pathol. 2010; 176(2):939-51. PMC: 2808098. DOI: 10.2353/ajpath.2010.090118. View

Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T . Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One. 2011; 6(11):e27339. PMC: 3208623. DOI: 10.1371/journal.pone.0027339. View

10.

Woodhouse E, Chuaqui R, Liotta L . General mechanisms of metastasis. Cancer. 1997; 80(8 Suppl):1529-37. DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1529::aid-cncr2>3.3.co;2-#. View

11.

Peppercorn J, Perou C, Carey L . Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008; 26(1):1-10. DOI: 10.1080/07357900701784238. View

12.

Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M . The prognostic relevance of fascin expression in human gastric carcinoma. Oncology. 2004; 67(3-4):262-70. DOI: 10.1159/000081327. View

13.

Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard M, Murray K . Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J Pathol. 2014; 233(3):238-46. DOI: 10.1002/path.4356. View

14.

Lin Q, Liu Y, Chen H, Liu Y, Tang Q, Liu J . Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer. Mol Clin Oncol. 2014; 1(5):839-844. PMC: 3915650. DOI: 10.3892/mco.2013.138. View

15.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

16.

Jiang P, Enomoto A, Takahashi M . Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett. 2009; 284(2):122-30. DOI: 10.1016/j.canlet.2009.02.034. View

17.

Mason B, Holdaway I, Mullins P, Yee L, Kay R . Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 1983; 43(6):2985-90. View

18.

Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G . Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995; 26(8):873-9. DOI: 10.1016/0046-8177(95)90010-1. View

19.

Gu M, Kim J, Park J . Fascin expression predicts lymph node metastasis and worse survival in small intestinal carcinoma. Pathology. 2013; 46(1):21-4. DOI: 10.1097/PAT.0000000000000024. View

20.

Vignjevic D, Schoumacher M, Gavert N, Janssen K, Jih G, Lae M . Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007; 67(14):6844-53. DOI: 10.1158/0008-5472.CAN-07-0929. View